News
-
Clinical Trial Highlights Positive Oncoprex Results In Lung Cancer Patients
4/27/2012
A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients.
-
Novartis Drug Afinitor® Approved By FDA As First Medication To Treat Patients With Non-Cancerous Kidney Tumors Associated With TSC
4/26/2012
Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets* for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery(2).
-
AstraZeneca To Acquire Ardea Biosciences For $1.26B Including Lead Product Lesinurad In Phase III Development For Gout
4/23/2012
AstraZeneca and Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.
-
Worldwide Clinical Trials Receives Recognition From ISR The CRO To Have On Your Radar
4/17/2012
Worldwide Clinical Trials Inc., a leading global provider of clinical research services, recently acknowledged receipt of strong ratings and recommendations from one of the industry’s leading independent market research firms, Industry Standard Research (ISR).
-
FDA Approves Amyvid™ (Florbetapir F 18 Injection) For Use In Patients Being Evaluated For Alzheimer's Disease And Other Causes Of Cognitive Decline
4/10/2012
Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.
-
AstraZeneca And Amgen Announce Collaboration To Jointly Develop And Commercialise Clinical-Stage Inflammation Portfolio
4/4/2012
AstraZeneca and Amgen recently announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).
-
Roche's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
4/2/2012
Roche recently announced topline results of EMILIA, the first randomised Phase III study of trastuzumab emtansine (T-DM1).
-
Shire Announces Top-Line Results Of The PREVENT2 Trial
4/2/2012
Shire plc., the global specialty biopharmaceutical company, recently announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis.1
-
Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis
3/29/2012
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY) ixekizumab (pronounced ix" e kiz' ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
-
Sanofi And Regeneron Report Phase 2 Data For Potential First-In-Class Lipid-Lowering PCSK9 Antibody
3/29/2012
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.